Additionally, the good prognosis was verified to be associated with elevated SPARCL1 level in a prostate cancer cohort (GSE16560, OS HR = 0.53, Cox p < 0.001) and a lung cancer cohort (GSE4573, OS HR = 0.57, Cox p = 0.04) and decreased SPARCL1 level in a colorectal cancer cohort (GSE17536, OS HR = 1.46, Cox p = 0.015; GSE17537, OS HR = 1.74, Cox p = 0.017) and an ovarian cancer cohort (GSE26712, OS HR = 1.17, Cox p = 0.033) (Figures 4F–J). This evidence concerns the gene SPARCL1 and ovarian cancer.